

SHEET 1 OF 1

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 18184-0018-01-US	INTERNATIONAL SERIAL NO. PCT/US2004/040403
		FILING DATE -	U.S. SERIAL NO. Not Yet Assigned
INFORMATION DISCLOSURE CITATION		APPLICANT(S): Steven M. LEVENTER, et al.	
		INTERNATIONAL FILING DATE: 03 December 2004	GROUP ART UNIT: Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>AH</i>	AA	US 6,080,736 A	06/27/2000	LANDRY et al			
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER <i>Alicia Hughes</i>	DATE CONSIDERED <i>10/24/2007</i>
EXAMINER: Initial if citation considered...whether or not citation is in conformance with M.P.E.P 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	

SUBSTITUTE FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 18184-0018-01-US	SERIAL NO. 10/578,522
OCT 16 INFORMATION DISCLOSURE STATEMENT <i>JUL 24 2006</i>		APPLICANT: Steven M. Leventer, et al.			
		FILING DATE May 8, 2006	GROUP Not Yet Assigned		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
art	AA 3,736,315	05/29/1973	Korosi, et al.	260	239	
art	AB Re. 30,014	05/29/1979	Körosi, et al.	260	239	
art	AC 4,322,346	03/30/1982	Kórösi, et al.	260	239	
ad	AD 4,423,044	12/27/1983	Kórösi, et al.	424	244	
ad	AE 4,614,740	09/30/1986	Láng, et al.	514	221	
ad	AF 4,835,152	05/30/1989	Korösi, et al.	514	220	
ad	AG 4,840,948	06/20/1989	Láng, et al.	514	221	
ar	AH 5,204,343	04/20/1993	Andrási, et al.	514	221	
art	AI 5,288,863	02/22/1994	Somogyi, et al.	540	567	
one	AJ 5,459,137	10/17/1995	Andrási, et al.	514	220	
art	AK 5,519,019	05/21/1996	Andrási, et al.	514	220	
al	AL 5,521,174	05/28/1996	Andrási, et al.	514	220	
art	AM 5,639,751	06/17/1997	Andrási, et al.	514	220	
an	AN 5,891,871	04/06/1999	Xia, et al.	514	219	
ak	AO 6,075,018	06/13/2000	Vágó, et al.	514	221	
ar	AP 6,080,736	06/27/2000	Landry, et al.	514	221	
aq	AQ 6,638,928	10/28/2003	Harris, et al.	514	221	
ar	AR 6,649,607	11/18/2003	Leventer, et al.	514	221	
as	AS 6,683,072	01/27/2004	Kucharik, et al.	514	211.13	
at	AT 6,864,251	03/08/2005	Kucharik, et al.	514	221	
au	AU 7,022,700	04/04/2006	Harris, et al.	514	221	
av	AV 2004/0138209	07/15/2004	Kucharik, et al.	514	221	
aw	AW 2004/0138210	07/15/2004	Harris, et al.	514	221	
ax	AX 2004/0152695	08/05/2004	Harris, et al.	514	221	
ay	AY 2004/0157833	08/12/2004	Harris, et al.	514	221	
az	AZ 2004/0162284	08/19/2004	Harris, et al.	514	221	
ba	BA 2004/0224943	11/11/2004	Leventer, et al.	514	221	
bb	BB 2004/0229867	11/18/2004	Kucharik	514	221	
bc	BC 2005/0075329	04/07/2005	Leventer, et al.	514	221	
bd	BD 2005/0288277	12/29/2005	Kucharik, et al.	514	221	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	<i>Resie Hefner</i>	DATE CONSIDERED	10/24/2007
----------	---------------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 18184-0018-01-US	SERIAL NO. 10/578,522
INFORMATION DISCLOSURE STATEMENT				APPLICANT: Steven M. Leventer, et al.	
				FILING DATE May 8, 2006	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
ark	BE	EP 0 492 485	12/31/91	Europe	C07D	491/04	
ark	BF	178516	3/31/83	Hungary	C07D	243/00	x
ark	BG	178519	3/31/83	Hungary	C07D	24300	x
ark	BH	WO 92/11262	7/9/92	WIPO	C07D	491/056	
ark	BI	WO 00/24400	5/4/00	WIPO	A61K	31/551	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ark	BJ	Y. Adachi et al., "Use of tofisopam (Grandaxin®) in autonomic imbalance and irritable bowel syndrome", <i>Igaku to Yakugaku</i> , 1987, 18(5), 1591-94, Japan. (Translation provided.)
ark	BK	T. Aoyagi et al., <i>Yakuri to Chiryo</i> , "Clinical evaluation of tofisopam (grandaxin®) in various unidentified gastrointestinal complaints", 1992, 20(2), 295-305, Japan. (Translation provided.)
ark	BL	S. Asano et al., "Study of the efficacy and safety of grandaxin tablets in vague complaints associated with gastrointestinal conditions", <i>Shinyaku to Rinsho</i> , 1993, 42(12), 95-100, Japan. (Translation provided.)
ark	BM	V.S. Chadwick, et al., "Activation of the mucosal immune system in irritable bowel syndrome", <i>Gastroenterology</i> , 2002, 122(7), 1778-83.
ark	BN	S.M. Collins, et al., "The putative role of inflammation in the irritable bowel syndrome", <i>Gut</i> , 2001, 49(6), 743-45.
ark	BO	M. Csillag et al., "The treatment of climacteric syndrome with tofizopam (grandaxin)", <i>Ther Hung</i> , 1975, 23(4), 164-69.
ark	BP	E. Fogassy, et al., "Studies on the Properties and Structure of Optically Active 1-(3,4-Dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-Benzodiazepine (Tofisopam). " in H.C. Van der Plas, et al. (Eds.) "Bio-Organic Heterocycles Synthetic, Physical Organic and Pharmacological Aspects", Elsevier, Amsterdam (1984).
ark	BQ	F. Galdiero, et al., "Effects of Benzodiazepines on Immunodeficiency and Resistance in Mice", <i>Life Sciences</i> , Vol. 57, No. 26, pp. 2413-2423, 1995
ark	BR	F. Gatta, et al., "Derivatives of 2,3-Benzodiazepine", <i>Il Farmaco, Ed. Sc.</i> 1985, 40, 942-
ark	BS	H. Hanajima, "Effects of tofisopam (granaxin on irritable colon and cardiac neurosis", <i>Yakuri to Chiryo</i> , 1987, 15(5), 307-17, Japan. (Translation provided.)
ark	BT	E. Horvath, et al., "Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia", <i>Progress in Neurobiology</i> , 2000, 60, 309-42.
ark	BU	S. Kalashnikov, et al., "Immunomodulating effects of tofizopam (Grandaxin®) and diazepam <i>in vitro</i> " <i>Mediators of Inflammation</i> , 2002, 11, 53-59.
ark	BV	A. Kato et al., "Clinical report on grandaxin for various unidentified complaints", <i>Yakuri to Chiryo</i> , 1987, 15(8), 163-71, Japan. (Translation provided.)
ark	BW	J. Kanto, et al., "Tofizopam: a benzodiazepine derivative without sedative effect", <i>International Journal of Clinical Pharmacology, Therapy and Toxicology</i> , 1982, 20(7), 309-12.

EXAMINER	<i>Robert Hughes</i>	DATE CONSIDERED	<i>10/24/2007</i>
----------	----------------------	-----------------	-------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 18184-0018-01-US	SERIAL NO. 10/578,522
INFORMATION DISCLOSURE STATEMENT				APPLICANT: Steven M. Leventer, et al.	
				FILING DATE May 8, 2006	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

arh	BX	S. Kishimoto et al., "Clinical effect of grandaxin on dyspeptic patients", <i>Yakuri to Chiryo</i> , 1989, 17(5): 457-64, Japan. (Translation provided.)
arh	BY	A. Kitano et al., "Clinical effect of tofisopam (grandaxin®) on vague gastrointestinal complaints", <i>Shinyaku to Rinsho</i> , 1988, 37(9), 169-73, Japan. (Translation provided.)
arh	BZ	M. Kojima, et al., "Effects of Tofisopam on Lower Digestive Tract Dysfunction", <i>Clinical Report</i> , 1996, 30(5), 989-94. (Translation provided.)
arh	CA	Y. Matsuo, et al., "Effect of Tofisopam on Experimental Ulcers", <i>Yakuri to Chiryo</i> , 1998, 16(8), 157-64. (Translation provided.)
arh	CB	M. Osipenko et al., "Role of grandaxin in the treatment of functional diseases of the gastrointestinal tract.", <i>Terapevt. Arkhiv</i> , 2000, 10, 23-27. (Translation provided.)
arh	CC	O. Oyesanmi, et al., "Hematologic Side Effects of Psychotropics", <i>Psychosomatics</i> , 199, 40(5), 414-21.
arh	CD	A. Pakkanen et al., "Comparative Study of the Clinical Effects of Tofizopam, Nitrazepam and Placebo as Oral Premedication", <i>Br. J. Anaesth.</i> , 1980, 52, 1009-12.
arh	CE	L. Petocz, et al., "The Main Pharmacological Characteristics of Grandaxin (Tofisopam, EGYT-341)", <i>Therapia Hungarica</i> , 1975, 23(4), 134-138.
arh	CF	L. Petócz, "A tofizopam (Grandaxin®) farmakológiai hatásai", <i>Acta Pharm. Hung.</i> 1993, 63, 79-82. (Translation provided.)
arh	CG	J. Ristelhueber, "Utility of a new anxiolytic, tofisopam, in current gastroenterology practice", <i>Revue Francaise de Gastro-Enterologie</i> , 1977, 125, 49-52, France. (Translation provided.)
arh	CH	M. Rizzo, "Chromatographic separation of 2,3-benzodiazepines", <i>Journal of Chromatography B</i> , 2000, 747, 203-16.
arh	CI	J. Szegő et al., "Selected passages from the clinical-pharmacological and clinical trials of grandaxin", <i>Acta Pharm. Hung.</i> , 1993, 63, 91-98, Hungary. (Translation provided.)
arh	CJ	H. Takada et al., "Clinical study of grandaxin for unidentified complaints", <i>Yakuri to Chiryo</i> , 1989, 17(3), 381-92, Japan. (Translation provided.)
arh	CK	I. Tarnawa, et al., "Structure-Activity Relationships of 2,3-Benzodiazepine Compounds With Glutamate Antagonistic Action", <i>Bioorg. & Med. Chem. Lett.</i> , 1993, 3(1), 99-104.
arh	CL	E. Tomori, et al., "Investigation of Metabolites of Tofizopam in Man and Animals", <i>Pol. J. Pharmacol. Pharm.</i> , 1984, 38, 423-30.
arh	CM	E. Tomori, et al., "Investigation of the Metabolites of Tofizopam in Man and Animals by Gas-Liquid Chromatography-Mass Spectrometry", <i>Journal of Chromatography</i> , 1982, 241, 89-99.
arh	CN	J. Visy, et al., "The Role of Configuration and Conformation in the Binding of 2,3-Benzodiazepines to Human Serum Albumin", <i>Chirality</i> , 1989, 1, 271-75.
arh	CO	K. Yamaguchi et al., "Tofisopam, a new 2,3-benzodiazepine. Inhibition of changes induced by stress loading and hypothalamic stimulation", <i>Can. J. Physiol. Pharmacol.</i> , 1983, 16, 619-25.

EXAMINER

DATE CONSIDERED

10/24/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 18184-0018-01-US	SERIAL NO. 10/578,522
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Steven M. Leventer, <i>et al.</i>	
		FILING DATE May 8, 2006	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.